Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma | Zendy

Thomas Kaley | Zendy; Katherine S. Panageas | Zendy; Ingo K. Mellinghoff | Zendy; Craig Nolan | Zendy; Igor T. Gavrilovic | Zendy; Lisa M. DeAngelis | Zendy; Lauren E. Abrey | Zendy; Eric C. Holland | Zendy; Andrew B. Lassman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma

Author(s) -

Thomas Kaley,

Katherine S. Panageas,

Ingo K. Mellinghoff,

Craig Nolan,

Igor T. Gavrilovic,

Lisa M. DeAngelis,

Lauren E. Abrey,

Eric C. Holland,

Andrew B. Lassman

Publication year - 2019

Publication title -

journal of neuro-oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.256

H-Index - 114

eISSN - 1573-7373

pISSN - 0167-594X

DOI - 10.1007/s11060-019-03243-7

Subject(s) - discontinuation , medicine , tolerability , oncology , clinical endpoint , toxicity , radiation therapy , phases of clinical research , nausea , clinical trial , neutropenia , surgery , adverse effect

Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability. It inhibits signaling through the PI3/AKT axis and other cascades of biologic importance in glioblastoma, and has promising pre-clinical activity in vitro and in vivo. Therefore, we conducted a phase II open-label single-arm clinical trial of perifosine for patients with recurrent glioblastoma (GBM).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research